New Vaccine Strategy for Mothers Could Shield Newborns From Deadly Superbug Infections

Harnessing Maternal Immunity to Combat Drug-Resistant Newborn Infections

A breakthrough study involving a mouse model suggests that maternal vaccination could serve as a powerful shield against Klebsiella pneumoniae, a pathogen responsible for high mortality rates among infants in developing nations. The findings, published in Science Advances, indicate that antibodies generated by vaccinated mothers are successfully passed to their offspring, providing significant protection against lethal bacterial strains.

Klebsiella pneumoniae represents a major global health challenge. In healthcare settings, it is a well-known cause of pneumonia, while in low- and middle-income regions, it frequently triggers severe, often fatal, neonatal sepsis. The situation is further complicated by the bacterium’s rising resistance to conventional antibiotics, leaving clinicians with few therapeutic options for the most vulnerable patients.

“Klebsiella pneumoniae is a serious threat to newborns who have not yet developed their own immune defenses,” says David A. Rosen, senior author of the study and an associate professor of pediatrics and molecular microbiology at Washington University School of Medicine in St. Louis. “Our study shows that maternal immunization can effectively bridge that critical window of vulnerability, giving newborns the protection they need right from birth.”

To evaluate the efficacy of maternal vaccination, researchers teamed up with the laboratory of Drew Schwartz, an assistant professor of pediatrics. They utilized a vaccine developed by the St. Louis-based company Omniose, which targets two particularly virulent types of the bacteria: K1 and K2. The experimental design involved immunizing female mice during mating and throughout their pregnancy.

The results were stark. When the researchers exposed two-week-old offspring to lethal doses of the bacteria, the protective effect of maternal immunity was clear. While the survival rate for pups born to unvaccinated mothers was 0% for the K1 strain and less than 35% for the K2 strain, more than 80% of pups from vaccinated mothers survived exposure to either type.

By monitoring the pups’ blood and the mothers’ breast milk over six weeks, the team identified high levels of vaccine-specific antibodies. These findings suggest that the antibodies are transferred both in utero and via nursing, conferring long-lasting protection. “Mice that were never immunized themselves are highly protected from a lethal infection just from the durable antibodies transferred to them from their mother,” explains lead author Paeton Wantuch, a staff scientist in the Rosen lab.

Looking ahead, the team is working to expand the scope of the vaccine to cover a broader range of global bacterial strains. Rosen believes this research provides a vital framework for future development. “This study presents the first evidence that giving moms a vaccine could be an effective strategy for protecting their babies against these severe infections,” he notes. “And it also has established a practical model that we can now use to test therapies and vaccines that will bring us one step closer to human clinical trials with the ultimate goal of impacting global health.”

Support for this research was provided by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Gates Foundation, and the Washington University Department of Pediatrics. The authors noted that several researchers involved in the project hold a financial stake in Omniose, the company developing the vaccine technology.